AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. by Wang, Jinfen et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177844
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Article 25fa pilot End User Agreement 
This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) 
with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either 
wholly or partially by Dutch public funds to make that work publicly available for no consideration 
following a reasonable period of time after the work was first published, provided that clear reference is 
made to the source of the first publication of the work.  
This publication is distributed under The Association of Universities in the Netherlands (VSNU) ‘Article 
25fa implementation’ pilot project. In this pilot research outputs of researchers employed by Dutch 
Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are 
distributed online and free of cost or other barriers in institutional repositories. Research outputs are 
distributed six months after their first online publication in the original published version and with 
proper attribution to the source of the original publication.  
You are permitted to download and use the publication for personal purposes. All rights remain with the 
author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised 
under this licence or copyright law is prohibited. 
If you believe that digital publication of certain material infringes any of your rights or (privacy) 
interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library 
will make the material inaccessible and/or remove it from the website. Please contact the Library 
through email: copyright@ubn.ru.nl, or send a letter to: 
University Library  
Radboud University 
Copyright Information Point 
PO Box 9100 
6500 HA Nijmegen 
 
You will be contacted as soon as possible. 
BIOMARKERS, GENOMICS, PROTEOMICS, AND GENE REGULATION
AKT Hyperactivation and the Potential of
AKT-Targeted Therapy in Diffuse Large B-Cell
Lymphoma
Jinfen Wang,*y Zijun Y. Xu-Monette,* Kausar J. Jabbar,* Qi Shen,* Ganiraju C. Manyam,z Alexandar Tzankov,x Carlo Visco,{
Jing Wang,z Santiago Montes-Moreno,k Karen Dybkær,** Wayne Tam,yy Govind Bhagat,zz Eric D. Hsi,xx J. Han van Krieken,{{
Maurilio Ponzoni,kk Andrés J.M. Ferreri,kk Shi Wang,*** Michael B. Møller,yyy Miguel A. Piris,k L. Jeffrey Medeiros,* Yong Li,zzz
Lan V. Pham,* and Ken H. Young*xxx
From the Departments of Hematopathology* and Bioinformatics and Computational Biology,z The University of Texas MD Anderson Cancer Center,
Houston, Texas; the Department of Pathology,y Shanxi Cancer Hospital, Shanxi, China; the Department of Pathology,x University Hospital, Basel,
Switzerland; the Department of Hematology,{ San Bortolo Hospital, Vicenza, Italy; the Department of Pathology,k Hospital Universitario Marques de
Valdecilla, Santander, Spain; the Department of Hematology,** Aalborg University Hospital, Aalborg, Denmark; the Department of Pathology,yy Weill
Medical College of Cornell University, New York, New York; the Department of Pathology and Cell Biology,zz Columbia University Medical Center and
New York Presbyterian Hospital, New York, New York; the Department of Pathology,xx Cleveland Clinic, Cleveland, Ohio; the Department of Pathology,{{
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; the San Raffaele H. Scientiﬁc Institute,kk Milan, Italy; the Department of
Pathology,*** National University Hospital, Singapore; the Department of Pathology,yyy Odense University Hospital, Odense, Denmark; the Department of
Cancer Biology,zzz Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio; and the University of Texas School of Medicine,xxx Graduate School of
Biomedical Sciences, Houston, Texas
Accepted for publication
April 6, 2017.
Address correspondence to Ken
H. Young, M.D., Ph.D.,
Department of Hematopathol-
ogy, The University of Texas
MD Anderson Cancer Center,
1515 Holcombe Blvd., Hous-
ton, TX 77030-4009. E-mail:
khyoung@mdanderson.org.
AKT signaling is important for proliferation and survival of tumor cells. The clinical signiﬁcance of AKT
activation in diffuse large B-cell lymphoma (DLBCL) is not well analyzed. Here, we assessed expression of
phosphorylated AKT (p-AKT) in 522 DLBCL patients. We found that high levels of p-AKT nuclear
expression, observed in 24.3% of the study cohort, were associated with signiﬁcantly worse progression-
free survival and Myc and Bcl-2 overexpression. However, multivariate analysis indicated that AKT
hyperactivation was not an independent factor. miRNA proﬁling analysis demonstrated that 63 miRNAs
directly or indirectly related to the phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin
pathway were differentially expressed between DLBCLs with high and low p-AKT nuclear expression. We
further targeted AKT signaling using a highly selective AKT inhibitor MK-2206 in 26 representative DLBCL
cell lines and delineated signaling alterations using a reverse-phase protein array. MK-2206 treatment
inhibited lymphoma cell viability, and MK-2206 sensitivity correlated with AKT activation status in DLBCL
cells. On MK-2206 treatment, p-AKT levels and downstream targets of AKT signaling were signiﬁcantly
decreased, likely because of the decreased feedback repression; Rictor and phosphatidylinositol 3-kinase
expression and other compensatory pathways were also induced. This study demonstrates the clinical and
therapeutic implications of AKT hyperactivation in DLBCL and suggests that AKT inhibitors need to be
combined with other targeted agents for DLBCL to achieve optimal clinical efﬁcacy. (Am J Pathol 2017,
187: 1700e1716; http://dx.doi.org/10.1016/j.ajpath.2017.04.009)
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Diffuse large B-cell lymphoma (DLBCL) is the most
common type of B-cell lymphoma. Patients with DLBCL
have highly variable clinical presentations and outcomes,
most likely explained by activation of a wide variety of
oncogenic pathways.1,2 On the basis of gene expression
proﬁling (GEP) or surrogate immunohistochemistry algo-
rithms, most cases of DLBCL can be classiﬁed into two
major cell-of-origin subtypes: prognostically favorable
germinal center B-cellelike (GCB) and the prognostically
unfavorable activated B-cellelike (ABC).1,3,4 However,
even within these two groups, there is much prognostic and
molecular heterogeneity.
The serine threonine protein kinase AKT (alias protein
kinase B) plays an important role in cell growth and survival
in many cancers. AKT has three isoforms (AKT1, AKT2,
and AKT3) encoded by three different genes with different
expression patterns.5,6 During activation, AKT is recruited
to the cell membrane by the binding of phosphatidylinositol-
triphosphate to its pleckstrin homology (PH) domain [a
process facilitated by phosphatidylinositol 3-kinase (PI3K)
and negatively regulated by phosphatase and tensin homo-
log (PTEN)],7 resulting in a conformational change that
facilitates phosphorylation (activation) at the Thr308 residue
by PDK1 and at the Ser473 residue by mechanistic target of
rapamycin complex 2 [mTORC2; comprising mTOR, Ric-
tor, target of rapamycin complex subunit LST8 (mLST8),
and mSin1].6,8 Phosphorylations at Ser473 and Thr308 are
regulated independently, and their interactions and impor-
tance are controversial.8e10 Activated AKT translocates to
the nucleus and phosphorylates many targets, leading to
inhibition of tuberous sclerosis complex 2 (TSC2), glycogen
synthase kinase 3b (GSK-3b), Bcl-2eassociated death
promotor (BAD), Bcl-2-like protein 11 (Bim), and Forkhead
box (FOXO) proteins and activation of mTORC1
[comprising mTOR, Raptor, mLST8, and proline-risk Akt
substrate of 40 kDa (PRAS40), ribosomal protein S6 kinase
(S6K), and X-linked inhibitor of apoptosis protein (XIAP)];
these changes in turn result in protein synthesis, cell cycle
progression, and suppression of apoptosis.5,8 The pro-
proliferation function of AKT1 is important for the onco-
genic transformation of epithelial tumors by Ras and Myc
overexpression, which depends on mTORC1 but is inde-
pendent of p53 inactivation and the antiapoptotic function of
AKT in one previous study.11 After tumor onset, AKT1
ablation and pharmacologic inhibition of AKT in vivo
resulted in regression of thymic lymphoma by modulating
Skp2 activities in the cell cycle (mediated by p27) and
apoptosis (mediated by FASL/FAS).12
A number of negative feedback mechanisms, including
those from S6K and PRAS40, exist in the PI3K/AKT/mTOR
pathway. mTORC1-inhibitor treatment results in enhanced
mTORC2 activity and AKT-Ser473 phosphorylation owing to
a decrease in feedback repression. Similarly, after PI3K in-
hibition or dual PI3K/mTOR inhibition, cancer cells
compensate by up-regulating genes involved in DNA dam-
age and expression and phosphorylation of several growth
factor receptor tyrosine kinases.5,8,9,13 The energy charge
(ATP/AMP ratio) of cells reﬂecting nutrient and stress status
may play a critical role in regulating the PI3K/AKT/mTOR
axis.10 It has been suggested that targeting AKT instead of
downstream mTORC1 may avoid the antiapoptotic effect
aside proliferation inhibition.11 A highly selective and potent
allosteric pan-AKT inhibitor, MK-2206, induces regression
of thymic lymphoma, simulating p53 restoration, even
though these tumors do not have AKT hyperactivation.12
MK-2206 can effectively block AKT signaling but has
limited antitumor activity when used as a single agent in
phase 1/2 clinical trials designed for patients with solid tu-
mors.6,14,15 In clinical trials for patients with acute myeloid
leukemia, MK-2206 demonstrated insufﬁcient clinical anti-
leukemic activity and resulted in only modest inhibition of
AKT signaling at maximum tolerated doses.16 Dual inhibi-
tion of AKT and mTOR resulted in synergistic antilymphoma
cytotoxicity in DLBCL cell lines.17
It has been shown that overexpression of phosphorylated
AKT (p-AKT) is associated with poor prognosis in patients
with a number of solid tumors18,19 and some hematologic
malignancies,20,21 including DLBCL.22e24 In the present
study we assessed p-AKT (Ser473) expression and AKT1
mutation status and evaluated their prognostic importance in
a large cohort of patients with de novo DLBCL treated with
R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone). We also correlated p-AKT with
expression of upstream and downstream biomarkers and
analyzed the associated gene and miRNA expression pro-
ﬁles. Moreover, we evaluated the cytotoxic effects of MK-
2206 in 26 human DLBCL cell lines and comprehensively
analyzed the altered expression and post-translational
modiﬁcations of key signaling proteins on MK-2206 treat-
ment in two representative DLBCL cell lines.
Materials and Methods
Patients
The study cohort, assembled as a part of the International
DLBCL Consortium Program study, consisted of 522 pa-
tients with de novo DLBCL treated with R-CHOP with a
median follow-up interval of 56 months. The study was
approved by the Institutional Review Board of The Uni-
versity of Texas MD Anderson Cancer Center (MD
Anderson). Cell-of-origin classiﬁcation was mainly deter-
mined by GEP (https://www.ncbi.nlm.nih.gov/geo;
accession number GSE31312) (n Z 405) in combination
with immunohistochemical algorithms (n Z 110).
Immunohistochemical Analysis
Immunohistochemistry analysis was performed on formalin-
ﬁxed, parafﬁn-embedded tissue microarrays to assess the
expression of phosphorylated AKT using a p-AKT (Ser473)
antibody (LP18; Leica, Vista, CA), IL-6 (Novus
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Biologicals, Littleton, CO), PI3K (610046; BD Labora-
tories, San Jose, CA), and other biomarkers on tissue
microarrays as previously described.4,25e31 Antigen
expression was scored in 5% increments by assessing the
percentage of immunoreactive tumor cells independently by
four senior experienced pathologists (K.J.J., Q.S., S.W., and
K.H.Y.) with 99% consensus. Discordant cases were
resolved by discussion under a multiheaded microscope.
AKT1 Sequencing
The coding region of AKT1 (1443 bp; https://www.ncbi.nlm.
nih.gov/genbank; GenBank accession number CCDS9994.1)
was sequenced using a Sanger sequencingebased method by
Polymorphic DNA Technologies Inc. (Alameda, CA). Single
nucleotide polymorphisms documented by the dbSNP
database have been excluded.
Methods for BCL2, BCL6, and MYC gene rearrangement
analysis, TP53 sequencing, and GEP analysis were
described previously.32,33
GEP and miRNA Proﬁling Analysis
Total RNA was extracted from formalin-ﬁxed, parafﬁn-
embedded tissue samples and subjected to GEP analysis. The
CELﬁles are deposited in theNationalCenter forBiotechnology
Information Gene Expression Omnibus repository (https://
www.ncbi.nlm.nih.gov/geo; accession number GSE31312).
Normalized microarray data were analyzed for differential
expression between subgroups. Univariate analysis was
performed to identify differentially expressed genes using the
t-test. The P values obtained by multiple t-tests were corrected
for false discovery rate using the beta-uniform mixture method.
miRNA proﬁling was performed using formalin-ﬁxed,
parafﬁn-embedded tissue sections by HTG Molecular Di-
agnostics Inc. (Tucson, AZ). miRNAs related to the PI3K/
AKT/mTOR pathway according to the literature or Tar-
getScan were selected. Expression levels of miRNAs were
compared using the unpaired t-test (two-tailed) and visual-
ized by the heatmap.
Cell Lines and the AKT Inhibitor Used in Cell Line Study
DLBCL cell lines MS, DS, DBr, JM (McA), FN, EJ, HF,
HB, MZ, LR, CJ, LP, WP, and RC were established at MD
Anderson and were characterized and described previ-
ously.31,34 The Pfeifer DLBCL cell line was purchased from
ATCC (Manassas, VA). The DLBCL cell lines U-2932,
OCI-LY19, DOHH2, Toledo, SUDHL-4, SUDHL-10,
HBL-1, TMD-8, HT, OCI-LY10, and OCI-LY3 were ob-
tained from outside sources. All cell lines were routinely
tested for Mycoplasma using a Myco Tect kit (Invitrogen,
Carlsbad, CA) and were validated by short tandem repeat
DNA ﬁngerprinting at the Characterized Cell Line Core
Facility at The University of Texas MD Anderson Cancer
Center. Stocks of authenticated cell lines were stored in
liquid nitrogen for future use, and all cell lines used in the
studies described here were from these authenticated stocks.
AKT inhibitor MK-2206 (Selleck Chemicals, Houston,
TX) were dissolved in dimethyl sulfoxide (Fisher Scientiﬁc,
Hampton, NH) to 100 mmol/L and 20 mmol/L stock solu-
tion, respectively, and diluted with culture medium when use.
Cell Culture and Cell Proliferation Assay
DLBCL cells were cultured at 37C in a 5% CO2 atmo-
sphere in RPMI-1640 medium (Gibco, ThermoFisher Sci-
entiﬁc, Waltham, MA) supplemented with 15% fetal bovine
serum (Gibco), 100 U/mL penicillin G, and 100 mg/mL
streptomycin (CellGro).
Brieﬂy, cells were seeded into 96-well plates at 50,000 cells
per well with varying concentrations ofMK-2206 added to the
wells. The total volume for each well is 200 mL. Dimethyl
sulfoxidewas used as a solvent control. The optical densitywas
measured at 450 nm on an enzyme-linked immunosorbent
assay reader using CellTiter 96 AQueous nonradioactive cell
proliferation assay with the Bio-Rad (Hercules, CA) bench-
mark microplate reader after 48 hours of incubation. Each
assay was performed in triplicate, and the mean values were
obtained from the results of three independent assays.
Western Blot Analysis
Protein was extracted using radioimmunoprecipitation assay
lysis buffer with phosphatase inhibitor cocktail and protease
inhibitor cocktail. Protein concentrations of the lysates were
determined using Bio-Rad protein assay reagent kit (Bio-Rad).
Equal amounts of total protein (50 mg) were resolved by SDS-
PAGE and transferred to a polyvinylidene ﬂuoride membrane
using the semidry transfer method. Membranes were blocked
with blocking buffer at room temperature for 20 minutes and
then incubated with the primary antibodies [AKT (pan) no.
4691 and anti-pAKT (Ser473) antibody no. 9271 (Cell
Signaling, Danvers,MA); Total AKT, dilution 1:1000; pAKT,
dilution 1:500; actin, dilution 1:10,000 (Sigma-Aldrich, St.
Louis, MO)] overnight at 4C. After washing three times with
tris-buffered saline and Tween 20 buffer (Bio-Rad), mem-
branes were incubated with secondary antibody (goat anti-
rabbit, dilution 1:2000; goat anti-mouse, dilution 1:10,000) at
room temperature for 1 hour, followed by extensive washing
with tris-buffered saline and Tween 20 buffer. Bands were
detected using the HyGLO Quick Spray enhanced chem-
iluminescence system (Denville Scientiﬁc, Holliston, MA).
RPPA Analysis
Protein lysates extracted fromDLBCLcell lineswere analyzed
using reverse-phase protein array (RPPA) at MD Anderson
Functional Proteomics RPPACore. Brieﬂy, protein lysate was
collected from control and MK-2206etreated DLBCL cell
cultures after 24 and 48 hours. For total protein lysate prepa-
ration,media were removed, and cells were washed twice with
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ice-cold phosphate-buffered saline containing Complete pro-
tease and PhosSTOPphosphatase inhibitor cocktail tablets
(RocheApplied Science,Mannheim,Germany) and 1mmol/L
Na3VO4. Lysis buffer (1% Triton X-100, 50 mmol/L HEPES,
pH 7.4, 150 mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L
EGTA, 100 mmol/L NaF, 10 mmol/L NaPPi, 10% glycerol, 1
mmol/L phenylmethylsulfonyl ﬂuoride, 1 mmol/L Na3VO4,
and 10 mg/mL aprotinin) was added. Samples were mixed by
vortex frequently on ice and then centrifuged. Protein lysates
were adjusted to a 1 mg/mL concentration, and a serial dilution
of 5 concentrations was printed, with 10% of the samples
replicated for quality control (2470 Arrayer; Aushon Bio-
systems, Billerica,MA) on nitrocellulose-coated slides (Grace
Bio-Labs, Bend, OR). Immunostaining was performed using
a DakoCytomation-catalyzed system (Dako, Carpinteria,
CA) and diaminobenzidine colorimetric reaction. Slides were
scannedon aﬂatbed scanner to produce 16-bit tiff images. Spot
intensities were analyzed and quantiﬁed using Array-Pro
Analyzer to generate spot signal intensities. Relative protein
levels for each sample were determined by interpolation of
each dilution curve from the standard curve constructed by a
script in R-written Bioinformatics. All of the data points were
normalized for protein loading and transformed to linear values
that can be used for bar graphs. Normalized linear value was
transformed to log2 value, and then median-centered for
hierarchical cluster analysis and for heatmap generation. The
heatmap was generated in Cluster 3.0 (University of Tokyo,
Human Genome Center, Tokyo, Japan; http://cluster2.
software.informer.com/3.0, last accessed February 07, 2017)
as a hierarchical cluster using Pearson Correlation and a
center metric. The resulting heatmap was visualized in
Treeview version 3.0 (http://jtreeview.sourceforge.net, last
accessed February 07, 2017) and presented as a high
resolution .bmp format. Totally, 285 unique antibodies and
four secondary antibody-negative controls were analyzed.
Statistical Analysis
Clinicopathologic and molecular features were compared
using the Fisher exact or c2 test. Overall survival (OS) and
progression-free survival (PFS) were analyzed using the
Kaplan-Meier method, and differences between subgroups
were compared using the log-rank test. Multivariate analysis
was performed using the Cox proportional hazards regres-
sion model. The GraphPad Prism 6 (GraphPad Software,
San Diego, CA) and SPSS software version 19.0 (IBM
Corporation, Armonk, NY) were used. All differences with
P  0.05 were considered statistically signiﬁcant.
Results
p-AKT (Ser473) Is Predominantly Expressed in the
Nucleus in the DLBCL Samples
Nuclear p-AKT expression (variable levels, 5% to 100%)
was found in 371 of 522 DLBCL cases (71%) assessed by
immunohistochemistry. Figure 1A shows representative
p-AKT positive staining, and Figure 1B shows the histo-
gram for p-AKT nuclear expression in this cohort. The
mean level of nuclear p-AKT expression in the studied
patients was 33.3%. No signiﬁcant difference was found in
p-AKT levels between GCB and ABC subtypes
(Figure 1C).
Cytoplasmic p-AKT expression was rare and was detec-
ted in only 10 DLBCL tumors (levels, 3% to 100%),
including eight cases that also had 100% p-AKTþ nuclear
expression and two cases without p-AKT nuclear
expression.
p-AKT Nuclear Overexpression Is Associated with
Poorer Prognosis in DLBCL Patients
We used X tile software version 3.6.1 (Yale School of
Medicine, New Haven, CT) to determine the immunohis-
tochemical cutoff for p-AKT overexpression associated with
signiﬁcant prognostic impact with maximum speciﬁcity and
sensitivity. With the use of this method, the cutoff for p-
AKT nuclear overexpression (p-AKThigh) was set at 70%;
127 of 522 patients (24.3%) had p-AKThigh DLBCL. These
patients had signiﬁcantly worse PFS (P Z 0.0027) and OS
(P Z 0.047) than other patients with p-AKTlow DLBCL
(Figure 1D). The 5-year PFS rate was 45.8% for patients
with p-AKThigh DLBCL and 61% for patients with
p-AKTlow DLBCL (hazard ratio Z 1.54; 95% CI,
1.19e2.25). The frequencies of p-AKThigh were similar
among the GCB and ABC subtypes. In GCB-DLBCL,
p-AKT overexpression was associated with signiﬁcantly
lower PFS (P Z 0.015) but not OS (P Z 0.42) rate.
In ABC-DLBCL, the unfavorable effects associated with
p-AKThigh did not reach statistical signiﬁcance (OS,
P Z 0.10; PFS, P Z 0.14).
p-AKT Overexpression Is Associated with Myc and Bcl-2
Overexpression
We compared the clinical and molecular features of p-AKThigh
patients with p-AKTlow patients (Tables 1 and 2).4,25e32
Consistent with the role of PI3K in AKT activation,
the p-AKThigh group had a signiﬁcantly higher mean
level of PI3K expression than the p-AKTlow group
(Figure 1E). In addition, the p-AKThigh group had higher
frequencies of IL-6þ, Mychigh, Bcl-2high, p-STAT3high,
FOXP1high, wild-type-p53high, and BLIMP-1þ expres-
sion, and lower frequencies of TP53 mutations and
nuclear expression of NF-kB subunits p50, p52, and
c-Rel (Table 2).
The positive correlations between p-AKThigh and Bcl-
2high expression and negative NF-kB (p50, p52, and c-Rel)
nuclear expression were signiﬁcant in both the GCB and
ABC subsets. Mychigh was more frequent in p-AKThigh
patients with GCB-DLBCL, likely owing to the increased
frequency of MYC translocations. The association of
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p-AKThigh with IL-6, p-STAT3high, and BLIMP-1þ
expression and the negative correlation with TP53 muta-
tions were signiﬁcant only in the ABC subtype (Table 2 and
Figure 1, FeH).
To evaluate the contribution of Bcl-2, Myc, and p-STAT3
overexpression to the poorer survival associated with p-
AKThigh DLBCL, we compared the survival of p-AKThigh
and p-AKTlow DLBCL patients with and without Bcl-2,
Myc, and p-STAT3 overexpression. We found no differ-
ence in survival between p-AKThigh and p-AKTlow patients
in the Bcl-2high, Mychigh, MychighBcl-2high (double-positive,
DP), and p-STAT3high DLBCL subsets. However, within
the Bcl-2low, Myclow, non-DP, and p-STAT3low subsets,
p-AKThigh patients had signiﬁcantly worse PFS than
p-AKTlow patients (Figure 2). However, in these four
subsets (ie, Bcl-2low, Myclow, non-DP, and p-STAT3low),
the p-AKThigh groups all had signiﬁcantly higher mean
levels of Myc expression than the p-AKTlow groups; in the
Myclow, non-DP, and p-STAT3low subsets, the p-AKThigh
groups also had signiﬁcantly higher mean expression levels
of Bcl-2 (Figure 2).
Multivariate survival analysis for p-AKT overexpression
with adjustment for clinical parameters resulted in a
borderline P value for adverse impact on PFS in the overall
DLBCL cohort (Table 3). However, additional adjustment
for Myc/Bcl-2 overexpression and TP53 mutation status
showed that p-AKThigh was not a signiﬁcant independent
prognostic factor in overall DLBCL (for OS, PZ 0.64; for
PFS, P Z 0.33) or in the GCB- and ABC-DLBCL sub-
groups (data not shown).
Figure 1 Expression and prognostic analysis of phosphorylated AKT (p-AKT) expression in diffuse large B-cell lymphoma (DLBCL). A: Representative
immunohistochemistry (IHC) staining for p-AKT. B: Histogram of p-AKT immunohistochemistry scores in the DLBCL cohort. C: Scatter plot for nuclear
p-AKT (Nuc-p-AKT) expression in DLBCL patients. The mean levels of Nuc-p-AKT expression in the germinal center B-cellelike (GCB) and activated B-
cellelike (ABC) DLBCL subtypes are similar per IHC analysis. D: p-AKThigh expression (70% of tumor cells showing positive p-AKT nuclear staining) is
associated with signiﬁcantly poorer overall survival (OS) and progression-free survival in patients with DLBCL. E: Scatter plot for phosphatidylinositol
3-kinase (PI3K) expression in DLBCL patients. The p-AKThigh group has a signiﬁcantly higher mean level of PI3K expression than the p-AKTlow group.
FeH: Scatter plot for IL-6, Myc, and Bcl-2 expression by IHC in DLBCL patients. Compared with the p-AKTlow group, the p-AKThigh group has a
signiﬁcantly higher mean level of IL-6 expression in ABC-DLBCL, Myc expression in GCB-DLBCL, and Bcl-2 expression in both GCB- and ABC-DLBCL. Each
dot in the scattered plots represents the expression level in one patient. *P < 0.05, ***P < 0.001. Original magniﬁcation, 60.
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AKT1 and AKT2 mRNA Expression Correlates with
Different Prognostic Effects
The p-AKThigh and p-AKTlow groups did not show signif-
icant differences in AKT1/2 mRNA levels (P Z 0.56). In
addition, we analyzed the prognostic effects associated with
AKT1/2/3 mRNA expression. High levels of AKT1 mRNA
were associated with signiﬁcantly poorer survival (OS,
PZ 0.0032; PFS, PZ 0.0062) in DLBCL patients overall
and in the GCB and ABC subgroups. Similar prognostic
effects of AKT3 mRNA expression were observed but with
nonsigniﬁcant P values. In contrast, high AKT2 mRNA
levels were associated with better survival in DLBCL with
borderline P values (OS, P Z 0.09; PFS, P Z 0.078)
(Figure 3).
GEP Analysis
To better understand the molecular mechanisms for AKT
hyperactivation and its prognostic effect, we further
compared the gene expression proﬁles of p-AKThigh and
p-AKTlow patients and found 29 transcripts differentially
expressed with a false discovery rate <0.01 (Figure 4A)
and 251 signiﬁcant transcripts with a false discovery rate
threshold of 0.05. When GCB and ABC subtypes were
analyzed separately, gene signatures were identiﬁed
signiﬁcantly only in GCB-DLBCL (174 transcripts with a
false discovery rate <0.05) (Figure 4B and Table 4). Many
genes involved in immune responses (C1S, IL1R1, C3, C2,
CCL5, IFNGR1, CEBPD, HLA genes, and B2M ), extra-
cellular matrix, cell adhesion, collagen, cytoskeleton, and
Table 1 Clinicopathologic Features of DLBCL Patients with High or Low p-AKT Expression
Variable
DLBCL GCB-DLBCL ABC-DLBCL
p-AKThigh
(n Z 127)
p-AKTlow
(n Z 395) P
p-AKThigh
(n Z 61)
p-AKTlow
(n Z 204) P
p-AKThigh
(n Z 66)
p-AKTlow
(n Z 184) P
Age, years
<60 61 (48.0) 163 (41.3) 0.18 35 (57.4) 99 (48.5) 0.25 26 (39.4) 59 (32.1) 0.29
60 66 (52.0) 232 (58.7) 26 (42.6) 105 (51.5) 40 (60.6) 125 (67.9)
Sex
Male 73 (57.5) 228 (57.7) 1.0 37 (60.7) 115 (56.4) 0.66 36 (54.5) 110 (59.8) 0.47
Female 54 (42.5) 167 (42.3) 24 (39.3) 89 (43.6) 30 (45.5) 74 (40.2)
Stage
I/II 51 (42.1) 186 (48.4) 0.25 27 (47.4) 111 (56.1) 0.29 24 (37.5) 70 (39.1) 0.88
III/IV 70 (57.9) 198 (51.6) 30 (52.6) 87 (43.9) 40 (62.5) 109 (60.9)
B-symptoms
Absence 75 (62.0) 244 (65.2) 0.51 43 (75.4) 130 (67.7) 0.33 32 (50.0) 109 (62.3) 0.1
Presence 46 (38.0) 130 (34.8) 14 (24.6) 62 (32.3) 32 (50.0) 66 (37.7)
LDH level
Normal 45 (38.8) 143 (39.1) 1.0 22 (39.3) 79 (42.2) 0.76 23 (38.3) 63 (36.6) 0.88
Elevated 71 (61.2) 223 (60.9) 34 (60.7) 108 (57.8) 37 (61.7) 109 (63.4)
Number of extranodal sites
0e1 84 (70.0) 298 (78.2) 0.085 42 (73.7) 154 (79.4) 0.37 42 (66.7) 138 (76.7) 0.13
2 36 (30.0) 83 (21.8) 15 (26.3) 40 (20.6) 21 (33.3) 42 (23.3)
ECOG score
0e1 92 (81.4) 298 (84.2) 0.47 44 (84.6) 153 (86.0) 0.82 48 (78.7) 138 (81.7) 0.7
2 21 (18.6) 56 (15.8) 8 (15.4) 25 (14.0) 13 (21.3) 31 (18.3)
Tumor size, cm
<5 49 (57.6) 173 (57.5) 1.0 19 (51.4) 94 (60.3) 0.36 30 (62.5) 76 (54.3) 0.4
5 36 (42.4) 128 (42.5) 18 (48.6) 62 (39.7) 18 (37.5) 64 (45.7)
IPI score
0e2 71 (57.3) 243 (63.6) 0.24 38 (63.3) 136 (69.7) 0.35 33 (51.6) 100 (55.6) 0.66
3e5 53 (42.7) 139 (36.4) 22 (36.7) 59 (30.3) 31 (48.4) 80 (44.4)
Therapy response
CR 92 (72.4) 303 (76.7) 0.34 42 (68.9) 155 (76.0) 0.32 50 (75.8) 141 (76.6) 0.87
PR 19 48 8 24 11 24
SD 7 15 4 10 3 5
PD 9 29 7 15 2 14
Data are expressed as n (%) unless otherwise indicated. For therapy response, P values were calculated as CR versus other responses. Percentages were
calculated from the total number of patients whose data were available for the characteristic of interest. Not all patients had data available for every
characteristic.
ABC, activated B-cellelike; CR, complete response; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center
B-cellelike; IPI, international prognostic index; LDH, lactate dehydrogenase; p-AKThigh, high levels (70%) of phospho-AKT expression; p-AKTlow, low levels
(<70%) of phospho-AKT expression; PD, progressive disease; PR, partial response; SD, stable disease.
Implication of AKT Activation in DLBCL
The American Journal of Pathology - ajp.amjpathol.org 1705
metabolisms were down-regulated in p-AKThigh patients.
In contrast, MDM2 and MAP2K were up-regulated. When
analyzing PD-1/PD-L1/L2 genes in particular, we found
that p-AKThigh correlated with PD-L2 down-regulation in
GCB-DLBCL (Figure 4C).
miRNAs May Play an Important Role in p-AKT
Hyperactivation
In contrast to the lack of correlation between p-AKT and
AKT1 mRNA levels, we found 63 miRNAs related to the
PI3K/AKT/mTOR pathway that were signiﬁcantly differ-
entially expressed between the p-AKThigh and p-AKTlow
DLBCL groups (Figure 4D). For example, the mean
expression levels of miR-22-3p, miR-23a-5p, let-7c-5p,
let-7b-5p, miR-143-3p, miR-99a-5p, miR-125b-5p,
miR-125b-1-3p, miR-27a-5p, miR-320a/b/c/d/e, miR-204-
3p, and miR-425-3p (for all, P < 0.0001), miR-29c-5p
(P Z 0.0001), miR-214-5p (P Z 0.0005), miR-7-5p
(P Z 0.0008), and miR-222-5p (P Z 0.0092) were
signiﬁcantly lower in the p-AKThigh group, whereas the
mean expression levels of miR-17-5p (P < 0.0001), miR-
20a-5p (P Z 0.0018), and miR-20b-5p (P Z 0.0038)
were signiﬁcantly higher in the p-AKThigh group in the
overall DLBCL cohort and in the GCB and ABC subgroups.
AKT Mutation Appears to Have No Pathologic
Signiﬁcance in DLBCL
We sequenced the AKT1 genes in 192 DLBCL (103 GCB
and 86 ABC) samples. Nonsynonymous AKT1 mutations
(n Z 36) were detected in 32 of 192 samples (16.7%),
Table 2 Comparison of Molecular Features of DLBCL Patients with High or Low p-AKT Expression
Variable
DLBCL GCB-DLBCL ABC-DLBCL
p-AKThigh p-AKTlow P p-AKThigh p-AKTlow P p-AKThigh p-AKTlow P
IL-6 expression
Positive 24 (20.7) 40 (10.9) 0.011 8 (15.1) 21 (11.2) 0.48 16 (25.4) 19 (10.9) 0.011
PI3K expression
70% 40 (36.4) 98 (27.8) 0.095 16 (31.4) 44 (24.3) 0.22 24 (40.7) 52 (30.8) 0.2
p-STAT3 expression
>40% 25 (25.8) 45 (13.7) 0.008 7 (14.6) 17 (10.2) 0.44 18 (36.7) 28 (17.4) 0.006
Myc expression
70% 59 (46.8) 111 (28.9) <0.0001 31 (51.7) 41 (20.9) <0.0001 28 (42.4) 69 (37.5) 0.56
Bcl-2 expression
70% 82 (65.6) 160 (41.6) <0.0001 35 (59.3) 66 (33.2) <0.0001 47 (71.2) 94 (51.6) 0.006
Mychigh/Bcl-2high
þ 36 (28.8) 58 (15.1) 0.0006 15 (25.4) 17 (8.7) 0.0007 21 (31.8) 41 (22.3) 0.12
MYC translocation
þ 13 (15.7) 25 (10.1) 0.17 10 (27.8) 15 (12.4) 0.037 3 (6.4) 10 (7.9) 1.0
BCL2 translocation
Positive 23 (22.3) 50 (15.9) 0.14 20 (41.7) 44 (28.2) 0.11 3 (5.5) 6 (3.8) 0.7
TP53 mutation
Positive 15 (13.8) 87 (24.6) 0.017 10 (19.2) 53 (29.0) 0.21 5 (8.8) 34 (20.6) 0.045
WT-p53 expression
20% 32 (34.4) 57 (22.5) 0.027 14 (34.1) 29 (23.4) 0.22 18 (34.6) 28 (21.7) 0.089
Bcl-6 expression
>30% 103 (83.1) 284 (74.3) 0.05 54 (91.5) 170 (85.0) 0.28 49 (75.4) 114 (62.6) 0.069
CD10 expression
30% 59 (46.5) 146 (37.9) 0.095 51 (83.6) 132 (65.7) 0.007 8 (12.1) 14 (7.6) 0.31
FOXP1 expression
60% 93 (73.8) 208 (54.3) <0.0001 37 (61.7) 58 (29.1) <0.0001 56 (84.8) 150 (81.5) 0.16
BLIMP-1 expression
10% 42 (35.0) 83 (22.1) 0.008 10 (17.5) 25 (12.9) 0.39 32 (50.8) 57 (31.8) 0.01
NF-kB1/p50 nuclear expression
Positive 40 (38.1) 199 (56.7) 0.001 13 (25.0) 85 (47.5) 0.004 27 (50.9) 113 (66.1) 0.053
NF-kB2/p52 nuclear expression
Positive 16 (14.0) 123 (34.4) <0.0001 7 (13.2) 64 (35.2) 0.002 9 (14.8) 58 (33.3) 0.005
c-Rel nuclear expression
Positive 14 (13.0) 122 (35.5) <0.0001 5 (9.6) 61 (35.3) <0.0001 9 (16.1) 60 (35.3) 0.007
Data are expressed as n (%) unless otherwise indicated. Percentages were calculated as positive cases/total cases with results available. Bold indicates
signiﬁcant values.
ABC, activated B-cellelike; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cellelike; p-AKThigh, high levels (70%) of phospho-AKT
expression; p-AKTlow, low levels (<70%) of phospho-AKT expression; PI3K, phosphatidylinositol 3-kinase; WT, wild-type.
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including eight mutations in the PH domain, 22 in the cat-
alytic (protein kinase) domain, and ﬁve in the C-terminal
extension domain (Figure 5A). No correlation was observed
between AKT1 mutation status and p-AKT expression, and
no signiﬁcant prognostic difference was observed between
patients with AKT1 mutations (overall or domain-speciﬁc
mutations) and those without, either in overall DLBCL
(OS, P Z 0.82; PFS, P Z 0.94) or within the GCB and
ABC subsets. Among patients with p-AKT overexpression,
the four cases with mutated AKT appeared to have poorer
OS and PFS than cases with wild-type AKT, especially in
cases of GCB-DLBCL (one had mutation in the PH domain,
and two had mutations in the catalytic domain) (Figure 5, B
and C). However, these four mutated p-AKThigh cases also
had Myc and Bcl-2 overexpression. For the three GCB-
DLBCL cases, one had MYC translocation, one had BCL2
translocation, and one had both TP53 deletion and BCL6
translocation.
Figure 2 Prognostic and expression analysis of phosphorylated AKT (pAKT) overexpression (pAKThigh) in diffuse large B-cell lymphoma (DLBCL) with and
without Myc, Bcl-2, and phosphorylated STAT3 (pSTAT3) overexpression, as shown by the Kaplan-Meier curves and scatter plots. The cutoffs for Bcl-2high,
Mychigh, and pSTAT3high were 70%, 70%, and 50%, respectively. A: In the Bcl-2low subset, but not Bcl-2high subset, pAKThigh is associated with
signiﬁcantly worse progression-free survival (PFS). However, in both Bcl-2low and Bcl-2high subsets, Myc expression is signiﬁcantly higher in the pAKThigh group
than in the pAKTlow group. Within the Bcl-2low and Bcl-2high subsets, Bcl-2 expression does not show much difference between the pAKThigh and pAKTlow
groups. B: In the Myclow, but not the Mychigh subset, pAKThigh is associated with signiﬁcantly worse PFS. However, in the Myclow subset, both Myc and Bcl-2
levels are signiﬁcantly higher in the pAKThigh group than in the pAKTlow group. C: In the pSTAT3low subset, but not the pSTAT3high subset, pAKThigh is associated
with signiﬁcantly worse PFS. However, in the pSTAT3low subset, both Myc and Bcl-2 levels are signiﬁcantly higher in the pAKThigh group than in the pAKTlow
group. D: In the non e double-positive (DP) subset but not in the Mychigh/Bcl-2high (DP) subset, pAKThigh is associated with signiﬁcantly worse PFS. However,
in the non-DP subset, both Myc and Bcl-2 levels are signiﬁcantly higher in the pAKThigh group than in the pAKTlow group. In the scatter plots, each dot
represents the expression level in one patient. The mean expression levels in the pAKTlow group are indicated by blue lines; the mean expression levels in the
pAKTlow group are indicated by pink lines. *P < 0.05, **P < 0.01, ***P < 0.001.
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MK-2206 Reduces AKT Phosphorylation and Impairs
DLBCL Cell Viability
As another approach to unravel the regulation and role of
p-AKT in DLBCL and to assess the therapeutic potential of
targeting AKT, we investigated the antilymphoma activity of
the AKT inhibitor MK-2206 in a panel of human DLBCL cell
lines (17 GCB-DLBCL and 9 ABC-DLBCL cell lines). Cells
were treated with increasing doses of MK-2206 (0 to 25
mmol/L) for 48 hours and cell viability was assessed. Similar
Table 3 Multivariate Analysis for Nuclear p-AKT Overexpression in DLBCL, GCB-DLBCL, and ABC-DLBCL
Variable
Overall survival Progression-free survival
HR (95% CI) P HR (95% CI) P
DLBCL
IPI >2 2.47 (1.76e3.47) <0.001 2.27 (1.65e3.14) <0.001
Female sex 1.00 (0.71e1.40) 1.00 0.98 (0.71e1.35) 0.89
Tumor size >5 cm 1.33 (0.96e1.86) 0.09 1.27 (0.93e1.75) 0.13
B-symptoms 1.37 (0.97e1.94) 0.075 1.37 (0.99e1.91) 0.061
Nuclear p-AKThigh 1.30 (0.89e1.90) 0.18 1.40 (0.98e2.00) 0.068
GCB-DLBCL
IPI >2 3.51 (2.08e5.92) <0.001 3.40 (2.09e5.55) <0.001
Female sex 0.96 (0.57e1.61) 0.87 1.04 (0.64e1.685) 0.88
Tumor size >5 cm 1.50 (0.90e2.50) 0.12 1.45 (0.90e2.34) 0.13
B-symptoms 1.38 (0.82e2.33) 0.23 1.27 (0.77e2.10) 0.35
Nuclear p-AKThigh 1.15 (0.61e2.17) 0.67 1.39 (0.78e2.48) 0.27
ABC-DLBCL
IPI >2 2.36 (1.52e3.66) <0.001 2.337 (1.50e3.62) <0.001
Female sex 1.01 (0.64e1.59) 0.96 1.00 (0.64e1.58) 1.00
Tumor size >5 cm 1.40 (0.90e2.17) 0.14 1.41 (0.90e2.20) 0.13
B-symptoms 1.24 (0.78e1.96) 0.37 1.25 (0.79e2.00) 0.34
Nuclear p-AKThigh 1.43 (0.88e2.30) 0.15 1.45 (0.90e2.34) 0.13
ABC, activated B-cellelike; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cellelike; HR, hazard ratio; IPI, International Prognostic Index;
p-AKThigh, high levels (70%) of phospho-AKT expression.
Figure 3 Prognostic impact of AKT1/2/3
mRNA expression on overall survival, and
progression-free survival rates in patients with
diffuse large B-cell lymphoma.
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to previous studies in other cell lines,16,35 exposure to MK-
2206 impaired cell viability in a dose-dependent manner.
The reduction in cell viability was modest in most cell lines
with IC50 values ranging from 0.5 to 20 mmol/L (Figure 6A).
MK-2206 treatment decreased AKT phosphorylation but did
not affect total AKT levels in most DLBCL lines (Figure 6B).
MK-2206esensitive cells expressed a signiﬁcantly higher
level of p-AKT than MK-2206eresistant cells (Figure 6C).
Spearman’s rank correlation between MK-2206 sensitivity
and p-AKT activity was signiﬁcant in the representative
DLBCL cell lines (Figure 6D).
MK-2206 Inhibits AKT Signaling but Also Induces
mTORC2 and Compensatory Signaling Pathways
To understand the mechanisms of action of MK-2206, we
comprehensively analyzed the alteration of signaling
transduction cascades after AKT inhibition using RPPA in
two representative DLBCL cell lines, DOHH2 (GCB) and
LP (ABC), which were sensitive to MK-2206. Protein ly-
sates were prepared from control and MK-2206etreated
DLBCL cells after MK-2206 treatment (at IC75) for 24 or
48 hours. After quality control, expression data for a total
of 285 proteins were available for further analysis. Super-
vised hierarchical clustering detected a set of up-regulated
and down-regulated proteins after MK-2206 treatment in
each cell line (Figure 7A). Signiﬁcantly up-regulated and
down-regulated proteins were selected to generate a heat-
map for each cell line (Figure 7B) and are categorized in
Table 5.
p-AKT (Ser473) levels in both cell lines decreased
signiﬁcantly after MK-2206 treatment; p-AKT (Thr308)
levels were also down-regulated in DOHH2 cells. Down-
stream targets of AKT phosphorylation such as p-GSK-3b,
p-FoxO3a, p-eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1), p-PRAS40, mTOR, eukaryotic
translation initiation factor 4 G (eIF4G), p-p70-S6K, Cyclin-
B1/D1, FoxM1, XIAP, Hexokinase-II, hypoxia-inducible
factor (HIF)-1a, and vascular endothelial growth factor re-
ceptor (VEGFR)-2 were also down-regulated in DOHH2/LP
cells (Figure 7, C and D), whereas TSC-2, p27-Kip-1, Bim,
BAD, bcl2-associated X protein (Bax), FoxO3a, cleaved
Figure 4 Gene expression proﬁling and miRNA proﬁling analysis for phosphorylated-AKT (p-AKT) expression. A and B: Genes signiﬁcantly differentially
expressed between patients with high and low levels of p-AKT expression (p-AKThigh and p-AKTlow) in the overall diffuse large B-cell lymphoma (DLBCL) cohort
(false discovery rate <0.01) (A) and in the germinal center B-cellelike (GCB) subgroup (false discovery rate <0.05, fold change >1.68) (B). C: The p-AKThigh
group has signiﬁcantly lower levels of PDCD1L2 mRNA expression than the p-AKTlow group in GCB-DLBCL. D: miRNAs whose mean levels show signiﬁcant
differences between the p-AKThigh and p-AKTlow groups. **P < 0.01. ABC, activated B-cellelike.
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caspases, and E-Cadherin expression (but not GSK-3ab)
were up-regulated. In addition to the down-regulation of
proteins involved in cell cycle progression (eg, Cyclin-B1/
D1, CDK1, FoxM1, and Aurora B), proteins involved in
DNA repair [eg, checkpoint kinase 1 (ChK1), ataxia telan-
giectasia and Rad3-related, MutS protein homolog 2, MutS
protein homolog 6, Rad51, and proliferating cell nuclear
antigen (PCNA) and the tumor suppressors retinoblastoma
protein and polo-like kinase 1 were also down-regulated in
DOHH2 and/or LP cells after MK-2206 treatment
(Table 5)].
However, similar to a common phenomenon observed in
the use of mTOR inhibitors resulting from the loss of a
negative feedback loop,8,9 Rictor (mTORC2) and PI3K,
which activate p-AKT; protein tyrosine kinase p-FAK and
adaptor protein GRB2-associated binding protein 2, which
activate PI3K; and p-mitogen-activated protein kinase
(MAPK) kinase 1 (MEK1), p-p38 (MAPK14), and p-
MAPK (ERK2), which suggest activation of compensatory
signaling, were up-regulated in DOHH2 cells after MK-
2206 treatment; tyrosine kinase receptors platelet-derived
growth factor receptor (PDGFR)b and Axl (which activate
PI3K and AKT signaling), protein kinase Cs (PKCs)
(downstream of PDGFR and PI3K and regulated by
mTORC2), protein tyrosine kinase Lck, scaffolding protein
Caveolin-1, receptor proteinase-activated receptor, and
p-NF-kB-p65 were up-regulated in both DOHH2 and LP
cells; Notch1 and Notch3 were up-regulated in LP cells after
MK-2206 treatment. In contrast, p-HER3, focal adhesion
kinase (FAK), MEK1, and C-Raf were down-regulated in
DOHH2 and/or LP cells. PTEN and Src homology region-2
that negatively regulate the PI3K signaling were up-
regulated in DOHH2 cells after MK-2206 treatment
(Table 5).
Likely because of the enhanced mTORC2 activity, acti-
vation of the compensatory pathways, and decreased GSK-
3ab expression (Table 5),10,36,37 antiapoptotic Bcl-2 and
Mcl-1 after MK-2206 treatment were up-regulated in both
DOHH2 and LP cells. p53 and Myc were up-regulated in LP
cells but down-regulated in DOHH2 cells after MK-2206
treatment. Beclin (essential for autophagy) was up-
regulated in DOHH2 cells. In addition, programmed cell
death protein 1 ligand 1 (PD-L1) expression mediating
immunosuppression was signiﬁcantly increased after MK-
2206 treatment in LP cells (Table 5).
Discussion
Here, we explored the role and regulation of AKT activation
in DLBCL and the potential for AKT-targeted therapy. We
show that overexpression of nuclear p-AKT (Ser473)
Table 4 Genes Signiﬁcantly Differentially Expressed between p-AKThigh and p-AKTlow Cases in Overall DLBCL and in GCB-DLBCL
Functional categories
In DLBCL (FDR < 0.01) In GCB-DLBCL (FDR < 0.05)
Down-regulated genes Down-regulated genes Up-regulated genes
Immune response, cytokine
receptors, chemokine
C1S, IL1R1 CFH/CFHR1, C3, C1S, CCL5, IFNGR1, CEBPD,
HLA-B, B2M, HLA-F, C2, HLA-A, HLA-E, HLA-G
DEFB126
Apoptosis CARD16/CASP1, VDAC3, TMBIM6 MDM2
Signaling NBL1 CD63, SEL1L, PRKAR1A, WDR26, EFHD2, NBL1 MAP2K5, TSSK3
Gene expression, cell growth ZNF583, JUN, DUSP1,
CALD1
DUSP1, AEBP1, JUN, KLF9, RBPJ, NR3C1, GRN,
LMNA, RUNX1, HNRNPU
RPL37A, ANAPC13, SNAI3,
MRTO4, CEP97, HNRNPR, TTF2
Cell adhesion, cytoskeleton,
extracellular matrix,
exocytosis, migration,
metastasis, angiogenesis
TIMP2, COL6A1, COL1A2,
DCN, COL1A1, COL3A1,
COL5A2, PDPN
MXRA5, FN1, COL5A2, CD44, TIMP2, COL1A1,
BGN, SRGN, PARVA, ITGB2, DPYSL3, MMP2,
LAMP2, DST, SPARC, WDR1, TLN1, PDLIM5,
PSAP, SERPINF1, MIR21/TMEM49, CAPNS1,
ANXA7, ACTG1, EXOC4, SH3PXD2A, DYNLL2,
ABHD2, ACTB
JPH1
Metabolism FTL SOD2, NNMT, GLUL, ALDH2, FTH1, PIGY,
B4GALT1, FTL, APOE, CYBRD1, SERINC1,
RNASEK, CSGALNACT2, GLRX, PPP1CA, GPX4,
GPD2, GALC, CYB5R3, TATDN2
ATAD3B, FXN, AGPAT5
Degradation, protein folding,
sorting, transport,
trafﬁcking
CTSB, ZFAND5 SLC1A3, RAB31, ZFAND5, CALU, USP36,
UBE2L6, ATP6V0E1, ARNT, RAB35, SEC23B,
DNAJC3, SERINC3, PICALM, STX4, VPS53,
AP2S1
FKBP6, KCNK1, FBXO38, CACYBP
Differentiation AHNAK, SLFN5
Unknown function AKIRIN1 LOC100288387, LOC100129500, AKIRIN1,
MARVELD1, TMEM140
C3orf53, C6orf58, CXorf61,
LOC100129069, C18orf18,
PDZK1P1, LOC440957, RNFT2
The order of genes is based on fold-changes.
DLBCL, diffuse large B-cell lymphoma; FDR, false discovery rate; GCB, germinal center B-cellelike; p-AKThigh, high levels (70%) of phospho-AKT expression;
p-AKTlow, low levels (<70%) of phospho-AKT expression.
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(70%, p-AKThigh) was associated with signiﬁcantly poorer
PFS in DLBCL patients treated with R-CHOP. However,
p-AKThigh was associated with Bcl-2 and Myc over-
expression, and multivariate analysis indicated that p-
AKThigh was not an independent prognostic factor for
poorer survival. Such a prognostic effect of p-AKT (sig-
niﬁcant in the univariate analysis but not in the multivariate
analysis) was also observed by an earlier study in a smaller
patient cohort (n Z 97).23 These data suggest that the
adverse impact of AKT activation is indirect and depends on
downstream effectors.11 It is also possible that the adverse
prognostic impact of AKT for patients treated with R-CHOP
has been mitigated because rituximab could inhibit AKT
signaling,38 whereas AKT signaling up-regulates CD20
levels.39 The overlapping but also independent regulation
and function of p-AKT (Ser473) and p-AKT (Thr308) may
also have confounded the analysis. Although phosphoryla-
tion at Ser473 is generally thought necessary for the full
activation of p-AKT,9,10,40 p-AKT (Thr308) in the absence of
phospho-Ser473 can have partial function.41 In addition, it is
unclear whether the p-AKT (Ser473) antibody we used cross-
reacts with the p-AKT2 (Ser474) and p-AKT3 (Ser472) iso-
forms. Notably, mRNA expression of AKT1 and AKT2, the
two commonly expressed isoforms, was associated with
opposite prognostic impact in this DLBCL cohort
(Figure 3). Despite the limitation of its prognostic impact, p-
AKT hyperactivation may provide important information
after the prognostic stratiﬁcation by Myc and Bcl-2, how-
ever, because it was associated with signiﬁcantly poorer
PFS in patients with low levels of Myc or Bcl-2 expression
(Figure 2).
GEP analysis showed that many immune-related genes
were down-regulated in the p-AKThigh group, particularly in
GCB-DLBCL, whereas MDM2 and MAP2K which protect
cells from apoptosis were up-regulated. Surprisingly, many
genes involved in metabolism and the cytoskeleton were
also down-regulated in the p-AKThigh group, opposite to the
functions of AKT and mTOR. It is possible that the major
function of AKT is mediated through post-translational
modiﬁcation rather than at the transcriptional level. In
addition, the identiﬁed p-AKThigh signatures showed simi-
larity to the Mychigh and p50low GEP signatures (data not
shown), likely caused by the positive/negative correlation of
p-AKThigh with these two transcription factors.
Regarding AKT hyperactivation mechanisms, AKT1 is
rarely ampliﬁed in DLBCL,5,42 but several upstream genetic
alterations have been implicated, such as deletion or muta-
tion of PTEN43,44 and PIK3CA mutations.45 An activating
mutation in the AKT PH domain E17K has been shown in
solid tumors conferring resistance to AKT inhibitors.46 In
Figure 5 AKT1 mutation analysis. A: Illustration of the AKT1 protein domains and AKT1 mutations observed in the patients with diffuse large B-cell
lymphoma (DLBCL). B and C: Among patients with high levels of phosphorylated AKT (p-AKThigh), patients with AKT1 mutations (MUT) tend to have poorer
progression-free survival than patients with wild-type (WT) AKT1 in the overall DLBCL cohort (B) and in the germinal center B-cellelike (GCB) subgroup (C).
ABC, activated B-cellelike; PH, pleckstrin homology; UC, unclassiﬁable.
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this study we did not observe the activating E17K mutation
or a signiﬁcant prognostic impact of AKT mutations.
Although the four patients with nuclear overexpression of
AKT mutants tended to have a poorer prognosis, the number
of patients is small and the poorer survival can be attribut-
able to other genetic lesions (MYC, BCL2, or BCL6 rear-
rangement, or TP53 deletion).
Instead, our analysis suggested the IL-6/PI3K signaling
pathway and epigenetic regulation by miRNAs played
important roles for AKT hyperactivation in DLBCL. We
identiﬁed 63 miRNAs that were signiﬁcantly differentially
expressed between the p-AKThigh and p-AKTlow groups.
Among the down-regulated miRNAs in the p-AKThigh
group, miR-143 has been shown to have antioncogenic
function by repressing both the PI3K/AKT and MAPK
pathways.47 In contrast, miR-17-5p, which targets PTEN
that negatively regulates the PI3K/AKT pathway,48 was
up-regulated in the p-AKThigh group.
AKT is thought to be an effective therapeutic target in
cancers with PI3K/AKT/mTOR activation49 and in tumors
that are not driven by AKT activation.12 The antitumor ac-
tivity of MK-2206 is greater in some, but not all, breast
cancer cell lines with PTEN loss or PIK3CA mutation.50 Our
data show that the sensitivity of MK-2206 in DLBCL cell
lines correlated with AKT activation status, suggesting the
on-target effect of MK-2206 in DLBCL cells. Interestingly,
DOHH2 cells (GCB-DLBCL with MYC/BCL2 rearrange-
ments and wild-type p53) and LP (ABC-DLBCL with
mutated p53) cells demonstrated high MK-2206 sensitivity.
In vitro studies have shown that AKT activation increases
Myc protein stability owing to the inhibition of GSK-3.51 In
mouse models, AKT activation and Myc expression exhibit
synergistic actions in aggressive B-cell lymphomagenesis.52
After tumor onset in p53/mice, AKT1 ablation resulted in
regression of thymic lymphoma and increased the life span of
p53/ mice.12 The antilymphoma activity of MK-2206
observed in DOHH2 and LP DLBCL cell lines, and the
correlation between p-AKT overexpression and MYC rear-
rangement and Myc/Bcl-2 overexpression observed in this
DLBCL cohort, may suggest indirect targeting strategies for
DLBCL with aggressive oncogenic drivers.
We further analyzed AKT signaling using RPPA, a
high-throughput antibody-based technique for proteomics
studies. In line with the impaired cell viability, after
MK-2206 treatment, p-AKT (Ser473) and phosphorylated
targets were down-regulated, as shown by down-regulation
of p-GSK-3b, p-FoxO3a, p-4E-BP1, p-p70-S6K, p-S6,
p-PRAS40, and peyes-associated protein. mTOR, HIF-1a,
XIAP, VEGFR-2, Cyclin-B1, FoxM1, Cyclin-D1, eIF4G,
and Hexokinase-II, whereas p27-Kip-1, BAD, p53
up-regulated modulator of apoptosis, Bim, Bax, Bak,
E-Cadherin, FoxO3a, Beclin, and caspases (cleaved) were
up-regulated. However, several upstream proteins were also
up-regulated, such as Rictor (mTORC2), PI3K, PDGFRb,
Caveolin-1, Lck, p-FAK, and Axl (therefore p-PKC/PKC),
and MEK1, p38, and MAPK were activated likely as
compensatory pathways for AKT function after pharmaco-
logic inhibition. NF-kB-p65-pS536 (which was also
up-regulated by PI3K inhibitors)53 and Notch1/3 were also
induced. The limited efﬁcacy of MK-2206 also may be
explained by the up-regulation of Bcl-2 and Mcl-1 and
down-regulation of GSK-3ab and proteins involved in DNA
damage and repair. However, decreased DNA repair may
suggest synergy between MK-2206 and radiotherapy.42
Figure 6 Pharmacologic AKT inhibition by MK-
2206 in diffuse large B-cell lymphoma (DLBCL) cell
lines. A: The effect of 48 hours of MK-2206
treatment on the viability of human patient-
derived DLBCL cell lines relative to cells treated
with dimethylsulfoxide control. B: Western blot
analysis results of phosphorylated AKT (p-AKT) and
total AKT protein expression in LP, MS, DOHH2,
and Toledo cell lines after incubation with 20
mmol/L MK-2206 for 48 hours. C: Comparison of p-
AKT expression in MK-2206esensitive versus
eresistant cell lines. MK-2206 IC50 of 10 mmol/L
is considered sensitive and IC50 >10 mmol/L is
considered resistant. D: p-AKT assessed by RPPA is
plotted against the corresponding MK-2206 IC50 in
26 representative DLBCL cell lines. Waterfall graph
shows the IC50 value of MK-2206 for each cell line
(A). Correlation coefﬁcient was determined by the
Spearman’s rank correlation and two-tailed t-test.
**P < 0.01. PC, positive control; RPPA, reverse-
phase protein array.
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Notably, p53, Myc, and PD-L2 expression were up-
regulated in LP cells (ABC-DLBCL with mutated p53)
after AKT inhibition. In this DLBCL cohort, p-AKThigh was
associated with signiﬁcantly lower PD-L2 mRNA expres-
sion in GCB-DLBCL (Figure 4C), and a trend to lower
PD-L1 mRNA expression in ABC-DLBCL (P Z 0.16).
These results provide insights into the efﬁcacy of MK-2206
as a single agent and suggest that MK-2206 may be more
effective when combined with PI3K/mTORC2/1/Bcl-2/
Mcl-1/PD-L1 inhibitors.
Figure 7 Reverse-phase protein array analysis in MK-2206etreated DOHH2 and LP cell lines. A: Supervised hierarchical clustering heatmap of 285 proteins
analyzed in DOHH2 and LP cell lines. For each heatmap, the top three rows are triplicate controls, and the bottom six rows are MK-2206 (IC75) treatment for
24 and 48 hours, respectively. B: Heatmap for signiﬁcantly up-regulated and down-regulated proteins in DOHH2 and LP cell lines after MK-2206 treatment. Red
and green bars indicate up-regulation and down-regulation, respectively. C: Schematic illustration of the alterations of AKT signaling pathways after MK-2206
treatment. Detailed descriptions are in the main text. Green arrows and blunted lines indicate tumor-suppressing effects; red arrows and blunted lines
indicate tumor-promoting effects. D: Examples of down-regulated phosphorylated AKT (pAKT) and AKT target proteins signiﬁcant in both DOHH2 and LP cell
lines after MK-2206 treatment. ABC, activated B-cellelike; GCB, germinal center B-cellelike; PTK, protein tyrosine kinase.
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Conclusions
This study demonstrated that AKT hyperactivation in
approximately one-fourth of DLBCL patients was associ-
ated with signiﬁcantly inferior PFS. Although this prog-
nostic impact may depend on other associated oncogenic
events, evaluation of p-AKT expression is helpful for
prognostic stratiﬁcation and therapy selection. Pharmaco-
logic inhibition of AKT impaired AKT signaling and lym-
phoma cell viability in vitro. However, targeting AKT as
monotherapy has limited efﬁcacy owing to the induction of
upstream and compensatory signaling pathways, and com-
bination therapies are needed. These results have clinical
and therapeutic implications for DLBCL with AKT
hyperactivation and potentially also for DLBCL with MYC/
TP53 abnormalities.
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Table 5 Up- and Down-Regulated Proteins after MK-2206 Treatment in DOHH2 and LP Cell Lines
Functional categories
In DOHH2 (GCB-DLBCL) In LP (ABC-DLBCL)
Increased Decreased Increased Decreased
Cell cycle, checkpoint, DNA
damage response, DNA
replication, gene
expression
Histone-H3, eEF2K, p27-Kip-
1,* p16INK4a, 53BP1, p21,*y
Cyclin-E1,y ATM,y PARP-
cleavedy
Chk1, Rb_pS807_S811, PLK1,
Cyclin-B1,* FoxM1,* Rad51,
Chk1_pS296, PCNA, Rb, ATR,
UBAC1, GCN5L2, CDK1, MSH2,
MSH6, Chk1_pS345, CDC2-
p34, Chk2, Aurora-B
Pdcd4,* Cyclin-E1,
PARP-cleavedy
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FoxM1,* Chk1,
Aurora-B, MSH2, ATR,
CDC2-p34, Rb, MSH6,
UBAC1, CDK1, PCNA,
Chk1_pS296, ADAR1,
ARID1A, Cyclin-D1*
Apoptosis, autophagy Bcl-2, Mcl-1, Puma, Bim,*
Bad_pS112,* Caspase-7-
cleaved,* Caspase-3,* Bax,*
Beclin,* Caspase-9-cleaved,*
FoxO3a*
FoxO3a_pS318_S321,* p53,
Bid, XIAP*
Mcl-1, Bim,* Puma, Bcl-
2, Caspase-7,* Smac,
Bak, p53, Bad,*
Caspase-9*
Bcl2A1
Signaling, cell growth,
immune response
S6_pS235_S236,*
p38_pT180_Y182,
MEK1_pS217_S221,
NF-kB-p65_pS536, Rictor,*
PAR, PDGFR-b,*
MAPK_pT202_Y204, Lck,
PKC-a, PI3K-p110-a-R,*
PI3K-p85,* Tuberin (TSC2),*
PTEN,* Axl,* Caveolin-1,
PREX1, PKC-b-II_pS660,
PKC-a_pS657,y
FAK_pY397,*yIGFBP5,*y
SHP-2_pY542,*y Gab2,*y
Akt*y
Akt_pS473,* Akt_pT308,*
eIF4G,* TTF1, 4E-BP1_pS65,*
FAK, mTOR,* MEK1, c-Myc,*
HER3_pY1289,* c-Met,*
S6_pS240_S244*y
PAR, Lck, c-Myc,*
YAP_pS127,* Notch1,
Pdcd-1L1,* PKC-
a_pS657, Axl,*
Caveolin-1, PDGFR-b,*
Notch3, NF-kB-
p65_pS536,
PKC-d_pS664,
PKC-b-II_pS660
Akt_pS473,* eIF4G,*
p70-S6K_pT389,*
MEK1, 4E-BP1_pS65,*
PRAS40_pT246,*
C-Raf, mTOR*
Cell adhesion, gap junction,
extracellular matrix,
exocytosis, endocytosis,
angiogenesis
Fibronectin, Connexin-43,
Annexin-I, Annexin-VII,
Claudin-7,y CD44-My
TFRC, VEGFR-2* Connexin-43, E-
Cadherin,* Claudin-7,
Annexin-VII, CD44,
Annexin-Iy
Metabolism, hypoxia LDHAy Hif-1a,* GSK-3b_pS9,*
GSK-3ab_pS21_S9,*
Hexokinase-II,* ACC1,
ACC_pS79, GSK-3ab*
G6PD, ATP5A GSK-3b_pS9,* GSK-
3ab_pS21_S9,* SDHA,
Gys, Hexokinase-II,*
GSK-3ab*
Protein folding HSP27_pS82, Cyclophilin,
HSP27
HSP70 HSP27
The order of proteins is according to the fold-change at 24 hours after treatment.
*Proteins upstream or downstream of AKT signaling and Pdcd-1L1.
yProteins that showed increase only at 48 hours.
ABC, activated B-cellelike; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cellelike.
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